SCHLAGWORTE: Nuclidium
Nuclidium: CHF 26 million Series B extension round
Nuclidium, a clinical-stage radiopharmaceutical company, has announced the successful closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension round, bringing...
